Novartis Wraps Up Alcon Ownership, Forms New Eye Care Unit
This article was originally published in The Tan Sheet
Executive Summary
Novartis will create an eye care division, its second-largest unit and the fifth growth platform in its health care portfolio, with full ownership of Alcon, the world's largest eye care company.
You may also be interested in...
Hi-Tech Deal Broadens Akorn Consumer Business
Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.
Hi-Tech Deal Broadens Akorn Consumer Business
Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.
Novartis Makes Room For OTC Division Head On Executive Committee
Novartis gives its OTC unit a direct line to the chief executive in an organizational realignment designed to strengthen and streamline the consumer businesses.